Mangoceuticals, Inc. MGRX

Full chart Compare
Set alert

Price alert · MGRX

All alert types
0.22 USD -0.01 (-4.39%)

At closeNov 3, 2026, 6:34 PM EST

0.22 0.00 -0.46%

After hours · Nov 3, 6:34 PM ET

0.1964 Day range 0.2398
0.162 52-week range 2.41
YTD
-70.54%
1 year
-88.28%
Market cap
4.84M
Revenue (ttm)
866.79K
EPS (ttm)
-0.96
Shares out
2.49M
YTD return
-70.54%
1-year return
-88.28%
Volume
842.25K
Avg volume
3.31M
Open
0.2426
Previous close
0.228
Day's range
0.1964 – 0.2398
52-week range
0.162 – 2.41

2Y -2.1707 (-91.59%)

0.00002.00004.00006.0000Jan 25Jun 25Nov 25Mar 26Aug 260.1993

Key statistics

Enterprise value
4.40M
PEG ratio
0.00
Price / sales
7.11
Price / book
4.57
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
15.50%
Free cash flow
-2.16M
Total cash
490.24K
Total debt
285.05K
Return on equity
-108.44%
Short % of float
9.99%
50-day average
2.49
200-day average
3.94

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
MGRX Revenue — quarterly 68.76K
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MGRX Net income — quarterly -1.31M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MGRX EPS — quarterly -0.09
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

About Mangoceuticals, Inc.

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.

Sector
Healthcare
Industry
Health Information Services
Country
United States

News

Your note

Sign in to keep a note on MGRX — it syncs with the Stock Master app.

Insider holders

MGRX insider holders
InsiderRelationLatest transactionDateShares held
COHEN JACOB D.Chief Executive OfficerStock GiftAug 25, 20240
D'ALESSIO LORRAINE PAMELADirectorStock Award(Grant)Jun 2, 2024175,000
HAMILTON ALEX PDirectorSaleJun 25, 202450,000
HAMMER AMANDA ELIZABETHChief Operating OfficerStock Award(Grant)Jun 2, 2024175,000
JOHNSTON EUGENE MChief Financial OfficerStock Award(Grant)Oct 2, 2023200,000
MYERS KENNYDirectorStock Award(Grant)Jun 2, 2024175,000

Institution ownership

MGRX institution ownership
Holder% heldSharesValueReported
Ackerman Capital Advisors, LLC2.34%58,224144.40KSep 29, 2024
Captrust Financial Advisors0.69%17,07742.35KSep 29, 2024
Geode Capital Management, LLC0.35%8,75521.71KSep 29, 2024
Peak6 Investments Llc0.24%5,88414.59KSep 29, 2024
McCollum Christoferson Group LLC0.23%5,72014.19KSep 29, 2024
Two Sigma Securities, LLC0.10%2,5236.26KSep 29, 2024

Fund ownership

MGRX fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.27%6,60316.38KOct 30, 2024
Fidelity Total Market Index Fund0.13%3,2458.05KOct 30, 2024
Fidelity Series Total Market Index Fund0.06%1,5773.91KOct 30, 2024
Fidelity NASDAQ Composite Index Fund0.02%4521.12KOct 30, 2024